-- 受以色列和黎巴嫩宣布将停火延长三周的提振,韩国股市周五小幅高开。此前,双方于周四在白宫举行了会谈。 韩国综合股价指数(KOSPI)小幅上涨,开盘报6496.10点。韩国创业板指数(KOSDAQ)上涨0.2%,即2.11点,开盘报1176.42点。 此次会谈标志着以色列和黎巴嫩数十年来首次直接外交接触,对于自1948年以来一直处于战争状态的两国而言,这无疑是一项重大突破。 在伊朗问题上,美国总统特朗普表示,他不想在与伊朗达成协议的问题上操之过急。他表示,自己没有结束冲突的压力,而是专注于与伊朗达成尽可能好的协议。 特朗普声称美国完全控制着霍尔木兹海峡,并表示一旦伊朗达成协议,美国将获得通行权。他还表示,希望在停火期间限制德黑兰的石油收入。 特朗普警告说,如果伊朗拒绝谈判,美国可能会采取军事行动升级局势。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.